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Abstract
Background: Infection with high-risk human papillomaviruses (HPVs) such as HPV-16 is intimately associated with
squamous cell carcinomas (SCCs) of the anogenital tract and a subset of oropharyngeal carcinomas. Such lesions,
including pre-invasive precursors, frequently show multipolar mitoses and aneuploidy. The high-risk HPV-16-
encoded E7 oncoprotein has been shown to rapidly induce centrosome abnormalities thereby causing the
formation of supernumerary mitotic spindle poles and increasing the risk for chromosome missegregation. HPV-16
E7 has been found to rapidly induce centriole overduplication, in part, through the simultaneous formation of
more than one daughter centriole at single maternal centrioles (centriole multiplication). The precise molecular
mechanism that underlies HPV-16 E7-induced centriole multiplication, however, remains poorly understood.
Findings: Here, we show that human keratinocytes engineered to stably express the HPV-16 E7 oncoprotein
exhibit aberrant Polo-like kinase 4 (PLK4) protein expression at maternal centrioles. Real-time quantitative reverse
transcriptase (qRT-PCR) analysis of these cells revealed an increase of PLK4 mRNA levels compared to control cells.
Importantly, the ability of the HPV-16 E7 oncoprotein to induce centriole multiplication was found to correlate with
its ability to activate the PLK4 promoter and to up-regulate PLK4 mRNA.
Conclusions: These results highlight the critical role of PLK4 transcriptional deregulation in centriole multiplication
in HPV-16 E7-expressing cells. Our findings encourage further experiments to test transcriptional inhibitors or small
molecules targeting PLK4 to prevent centriole abnormalities, mitotic infidelity and malignant progression in HPV-
associated neoplasms and other tumors in which PLK4 regulation is disrupted.
Introduction
Infection with high-risk human papillomavirus type 16
(HPV-16) is the leading cause of squamous cell carcino-
mas (SCCs) of the anogenital tract as well as a subset of
oropharyngeal carcinomas [1]. Such neoplasms are com-
monly genomically unstable and the HPV-16 E7 onco-
protein, together with the E6 oncoprotein, has been
shown to play a crucial role in the loss of host cell gen-
ome integrity [2].
The HPV-16 E7 oncoprotein disrupts the G1/S-phase
cell cycle checkpoint on multiple levels to promote
unscheduled entry into S-phase and viral genome repli-
cation by the host cell DNA replication machinery [3].
High-risk HPV-16 E7 binds and degrades the retinoblas-
toma tumor suppressor protein (pRB) and inactivates
histone deacetylases type -1 and -2 (HDAC-1 and -2)
through interaction with Mi2b[4,5]. The HPV-16 E7
oncoprotein has also been shown to interact with tran-
scription factors such as E2F-1 and E2F-6 as well as
cyclin/CDK2 complexes [6-9]. Together, these activities
not only help to establish a replication-competent milieu
in differentiated host keratinocytes but also set the stage
for host cellular changes that can promote the progres-
sive loss of genome integrity [10].
Genomic stability is maintained, in part, by the strict
control of centriole duplication [11]. Centrioles are the
core-forming units of centrosomes, cellular organelles
that play a critical role in both cilia and mitotic spindle
pole formation [12]. The single centrosome of a non-
dividing cell consists of a pair of centrioles, barrel
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shaped microtubule cylinders, embedded in pericentrio-
lar material [12]. The centrosome duplicates exactly
once prior to mitosis in order to form two spindle
poles. Deviation from this rule has potentially cata-
strophic consequences since it can result in supernu-
merary spindle poles and a defective cell division
[13,14]. Centrosome duplication begins in late mitosis/
early G1-phase of the cell division cycle following cen-
triole separation [15] and recruitment of a protein
kinase, polo-like kinase 4 (PLK4), to the wall of the pre-
existing, or maternal centrioles, at the site of daughter
centriole synthesis [16]. Each maternal centriole serves
as a platform for the assembly of normally only one
daughter centriole. Centrosome duplication completes
during the late-G2 phase of the cell division cycle, when
the two centriole pairs split to form the mitotic spindle
poles.
HPV-16 E7 oncoprotein expression disrupts normal
centriole duplication control resulting in the rapid
induction of centriole overduplication [17]. This has
previously been shown to involve centriole multiplica-
tion [18]. This novel pathway is characterized by a single
maternal centriole initiating the abnormal simultaneous
synthesis of two or more daughter centrioles [18]. Stu-
dies in human papillomavirus (HPV)-associated primary
human tumors were among the first to demonstrate
that centrosome overduplication does in fact occur in
human tumors and that the presence of centrosome
overduplication correlates with cell division errors [19].
Recently, it was discovered that centriole multiplica-
tion involves deregulation of cyclin E/CDK2 complexes,
which promote the aberrant recruitment of PLK4 to
maternal centrioles [20]. At the same time, however, it
was shown that PLK4 protein levels are rate-limiting for
centriole multiplication [20]. The present study was
therefore designed to examine whether and how the
HPV-16 E7 oncoprotein interferes with PLK4 expression
to stimulate centriole overduplication.
Findings and Discussion
PLK4 is required for HPV-16 E7-induced centriole
overduplication and is aberrantly recruited to maternal
centrioles
Depletion of PLK4 protein by small interfering RNA
(siRNA) was found to impair the ability of HPV-16 E7
to induce centriole overduplication in U-2 OS/centrin-
GFP cells (Figure 1A; Materials and Methods can be
found in Additional File 1). The proportion of cells with
more than four centrioles was significantly reduced
from 11.6% in control siRNA transfected HPV-16 E7
expressing cells to 2% in PLK4-depleted HPV-16 E7
expressing cells (p ≤ 0.002; Figure 1A). This result
demonstrates that HPV-16 E7 requires PLK4 to pro-
mote centriole multiplication and is in line with
previous findings that PLK4 is the rate-limiting factor in
this process [20].
We next determined whether PLK4 protein localiza-
tion is altered in the presence of HPV-16 E7. Non-trans-
formed normal human keratinocytes transduced with
either a control plasmid (LXSN) or a plasmid expressing
HPV-16 E7 (kindly provided by Susanne Wells, Univer-
sity of Cincinnati, OH, USA) were transiently trans-
fected with a centrin-GFP plasmid (kindly provided by
Michel Bornens, Institut Curie, Paris, France [21]) to
visualize centrioles followed by immunofluorescence
microscopic analysis for endogenous PLK4 (antibody
kindly provided by Erich Nigg, University of Basel, Swit-
zerland [22]). In control cells, disengaged centrioles
were commonly associated with a single dot of PLK4
localized in close proximity to the site of daughter cen-
triole assembly at the wall of maternal centrioles (Figure
1B, LXSN). In cells stably expressing HPV-16 E7, an
increased proportion of cells with two or more dots of
endogenous PLK4 at single mothers was detected (Fig-
ure 1B, HPV-16 E7). Aberrant PLK4 dots at maternal
centrioles were detected in 29 of 86 (33.7%) cells expres-
sing the control plasmid LXSN (Figure 1C). Stable
expression of HPV-16 E7 led to a 1.5-fold increase in
comparison to controls with aberrant PLK4 dots at
maternal centrioles in 45 of 89 cells (50.6%; p ≤ 0.05;
Figure 1C).
It is noteworthy that a high percentage of control cells
displayed aberrant PLK4 dots at maternal centrioles
(33.7%). The frequency of centriole overduplication in
control cells was 4% whereas 8.3% of HPV-16 E7-trans-
duced keratinocytes showed centriole overduplication (p
≤ 0.05) while 50.6% of the latter cells showed aberrant
PLK4 dots. The discrepancy between aberrant PLK4
recruitment to maternal centrioles and actual centriole
overduplication is obvious and in line with a previous
report [20]. One reason could be the highly unstable
nature of the PLK4 protein [23] but it is also possible
that the recruitment of PLK4 is reversible. In addition, it
is possible that the target or targets of PLK4 kinase
activity may not always be present at effective concen-
trations to initiate aberrant daughter centriole
formation.
HPV-16 E7 expression up-regulates PLK4 mRNA levels
Since it has previously been reported that PLK4 mRNA
levels tightly correlate with PLK4 protein expression, we
decided to analyze PLK4 transcription in HPV-16 E7
expressing cells [24,25]. We performed real-time quanti-
tative reverse transcriptase polymerase chain reaction
(qRT-PCR) analysis of PLK4 mRNA in human keratino-
cytes transduced with either a control plasmid (LXSN)
or a plasmid expressing HPV-16 E7. We found that
stable expression of HPV-16 E7 led to a moderate
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Figure 1 HPV-16 E7 induces centriole overduplication through transcriptional deregulation and aberrant recruitment of PLK4 to
maternal centrioles. (A) Quantification of centriole overduplication (>4 centrioles per cell) in U-2 OS/centrin-GFP cells transfected with either
control (siControl) or PLK4 (siPLK4) siRNA duplexes for 24 h followed by ectopic expression of HPV-16 E7 for another 48 h. Mean and standard
error of at least three independent experiments with at least 100 cells counted per experiment are shown. Asterisk indicates statistically
significant differences (p ≤ 0.002). (B) Immunofluorescence microscopic analysis of human keratinocytes transduced with either empty vector
(LXSN) or HPV-16 E7 for endogenous PLK4 following transiently transfected with centrin-GFP (48 h). Arrows indicate PLK4 dots at maternal
centrioles. Note the presence of two dots in a HPV-16 E7-expressing cell (bottom panels). (C) Quantification of the percentage of cells with
aberrant (two or more) PLK4 dots at maternal centrioles in human keratinocytes transduced with either a control plasmid, LXSN, or HPV-16 E7.
Asterisk indicates statistically significant differences (p ≤ 0.05). (D) Quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR)
analysis for PLK4 mRNA was performed on total RNA isolated from human keratinocytes expressing either a control plasmid, LXSN, or HPV-16 E7.
bactin was used as a control housekeeping gene. Experiments were performed in triplicate and analyzed as described in the Materials and
Methods section (Additional File 1). Asterisks indicate statistically significant differences (p ≤ 0.01). (E) Fluorescence microscopic analysis of U-2
OS/centrin-GFP cells transfected with either an empty vector control plasmid (pCMV-Neo) or E2F-1 for 48 h. Nuclei stained with DAPI. Scale bar
indicates 10 μm. (F) Quantification of centriole multiplication (>4 centrioles, >1 daughter at one or more maternal centrioles) in U-2 OS/centrin-
GFP cells ectopically expressing either a control plasmid or E2F-1 for 48 h. Mean and standard error of two independent experiments with a
triplicate of at least 100 cells counted per experiment are shown. Asterisk indicates statistically significant differences (p ≤ 0.002). (G)
Quantification of PLK4 promoter activity following transient co-transfection (48 h) of U 2-OS/centrin-GFP cells with the PLK4 promoter construct
(pGL3-PLK4) and a transfection control (pRL-CMV) with either an empty vector control (Control) or E2F-1. The bar graph shows fold activation of
the PLK4 promoter when compared with the empty luciferase construct, pGL-3, from three independent transfections, and expressed as mean
and standard error. Asterisks indicate statistically significant differences (p ≤ 0.001). (H) Table comparing quantification of centriole
overduplication (>4 centrioles), PLK4 promoter activation, and PLK4 mRNA upregulation in U-2 OS/centrin-GFP cells ectopically expressing the
indicated construct for 48 h and analyzed as described in the Materials and Methods section (Additional File 1).
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(1.3-fold) increase of PLK4 mRNA levels in comparison
to control cells (p ≤ 0.01; Figure 1D).
HPV-16 E7 oncoprotein expression leads to deregula-
tion of E2F-mediated gene transcription through its
chromatin remodeling activities as well as its ability to
interact with E2Fs [6,7]. Using a computation-based
transcription factor prediction program (TFSearch;
http://www.cbrc.jp/research/db/TFSEARCH.html) and
analyzing the sequence of the PLK4 gene 1698 bp
upstream and 102 bp downstream of the transcription
initiation site, we were not able to locate putative E2F-
binding sites. However, we did find binding sites for the
SP-1 transcription factor within this PLK4 promoter
region and SP-1 has been demonstrated to cooperate
with E2F-1 to activate gene transcription [26].
Based on the above findings, we transiently overex-
pressed E2F-1 (plasmid kindly provided by Jacqueline
Lees, MIT, Cambridge, MA, USA), in U-2 OS/centrin
GFP cells and assayed for centriole multiplication. Over-
expression of E2F-1 led to a statistically significant 7.7-
fold increase in centriole multiplication from 0.6% in
control transfected cells to 4.6% in E2F-1 transfected
cells (p ≤ 0.001; Figure 1E and 1F). E2F-1 overexpres-
sion was also able to activate the PLK4 promoter. Luci-
ferase activity of a pGL3-based firefly luciferase PLK4
promoter construct (kindly provided by Yi Sun, Univer-
sity of Michigan, Ann Arbor, MI, USA [27]) was found
to be enhanced 2.1-fold in the presence of E2F-1 in U-2
OS/centrin GFP cells compared to control transfected
cells (p ≤ 0.002; Figure 1G).
Our results show that both the HPV-16 E7 oncopro-
tein and the transcription factor E2F-1 can stimulate
centriole multiplication and that this function correlates
with the ability to activate the PLK4 promoter.
PLK4 promoter activation by HPV-16 E7 correlates with
the induction of centriole overduplication
Next, we confirmed that PLK4 mRNA levels were not
increased following transient expression of either high-
risk HPV-16 E6, low-risk HPV-6 E6 or low-risk HPV-6
E7, none of which mediate centriole overduplication
(Figure 1H; [17]). Having determined that up-regulation
of PLK4 mRNA was promoted only by high-risk HPV-
16 E7 expression, we wanted to explore what functional
domains of the E7 oncoprotein were responsible for
deregulating PLK4 mRNA levels.
Expression of an HPV-16 E7 mutant with deletion of
the amino acid region 21-24, which contains the
LCXCE motif (HPV-16 E7 Δ21-24; kindly provided by
Karl Münger, The Channing Laboratory, Brigham and
Women’s Hospital, Harvard Medical School, Boston,
MA, USA) and is deficient in both pRB binding and
degradation completely lacked the ability to induce cen-
triole overduplication, as has been previously reported
(Figure 1H; [28]). Further, an HPV-16 E7 amino acid
substitution mutant L67R (HPV-16 E7 L67R; obtained
from Karl Münger through Addgene), which is unable
to interact with HDACs [4,5], was also unable to induce
centriole overduplication to the same extent as wild-
type HPV-16 E7 (Figure 1H). This mutant can bind pRB
but has a reduced ability to suppress the pRB-induced
flat cell phenotype in Saos-2 cells. It has also a reduced
protein stability compared to wild-type HPV-16 E7
[4], which makes the interpretation of this result
challenging.
We analyzed next whether the ability of the HPV-16
E7 constructs to induce centriole overduplication corre-
lated with their ability to activate the PLK4 promoter
and up-regulate PLK4 mRNA. Luciferase activity of the
PLK4 promoter construct was enhanced in the presence
of wild-type HPV-16 E7 (1.4-fold) but not the HPV-16
E7 mutant constructs (p ≤ 0.01; Figure 1H). In line with
the ability of the wild-type HPV-16 E7 oncoprotein to
induce PLK4 promoter activation, PLK4 mRNA tran-
scription was increased 1.7-fold following transient
expression of wild-type HPV-16 E7 but not the HPV-16
E7 mutant constructs (p ≤ 0.01; Figure 1H). Taken
together, these results show an excellent correlation
between the ability to induce centriole overduplication
and PLK4 promoter activation and mRNA upregulation.
Taken together, our findings depict a mechanism for
the rapid induction of centriole multiplication by the
HPV-16 E7 oncoprotein. Disruption of the pRB-signal-
ing axis, likely in concert with HDAC-1 and -2 interac-
tion, by HPV-16 E7 promotes the up-regulation of
PLK4 mRNA. Deregulation of cyclin E/CDK2 com-
plexes, along with an increase of PLK4 transcription,
leads to the aberrant recruitment of excess PLK4 protein
to maternal centrioles in the form of multiple PLK4
dots. HPV-16 E7 can interfere with two steps of cen-
triole biogenesis to induce centriole multiplication,
namely the increase in PLK4 expression level and the
recruitment of PLK4 to maternal centrioles. PLK4 is
highly unstable and it is possible that HPV-16 E7 may
also interfere with post-translational regulatory mechan-
isms to increase PLK4 abundance at maternal centrioles.
Support for the important role of gene transcription in
HPV-16 E7 induced centriole overduplication comes
from a previous study which showed that ongoing RNA
polymerase II transcription is necessary for HPV-16 E7
induced centriole overduplication but dispensable for
normal centriole duplication [29]. This is in line with
findings presented here that up-regulation of PLK4
mRNA transcripts correlates with the ability of HPV-16
E7 to induce centriole multiplication.
Collectively, these results highlight the critical role of
PLK4 transcriptional deregulation in centriole multipli-
cation in HPV-16 E7-expressing cells. Our findings
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encourage further experiments to test transcriptional
inhibitors or small molecules targeting PLK4 to prevent
centriole abnormalities, mitotic infidelity and malignant
progression in HPV-associated neoplasms or other
tumors in which PLK4 regulation is found to be
disrupted.
Additional material
Additional file 1: Materials and Methods. A description of all materials
and experimental procedures used in this study.
Acknowledgements
We would like to thank Amy Gardiner and Saleem Khan for invaluable help
with qRT-PCR experiments. We thank Michel Bornens, Jacqueline Lees, Karl
Münger, Erich A. Nigg, Yi Sun and Susanne Wells for sharing important
reagents. This work was supported by NIH/NCI grant R01 CA112598, a
Research Scholar Grant from the American Cancer Society (RSG-07-07501, to
SD) and the University of Heidelberg School of Medicine and Department of
Urology (SD).
Author details
1Cancer Virology Program, University of Pittsburgh Cancer Institute,
Pittsburgh, PA 15213, USA. 2Molecular Virology and Microbiology Graduate
Program, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261,
USA. 3Section of Molecular Urooncology, Department of Urology, University
of Heidelberg School of Medicine, 69120 Heidelberg, Germany. 4Department
of Microbiology and Molecular Genetics, University of Pittsburgh School of
Medicine, Pittsburgh, PA 15261, USA.
Authors’ contributions
BT performed PLK4 promoter luciferase activity assays. NK performed all
other experiments described in this manuscript. NK and SD conceived the
project. NK and SD analyzed the results and wrote the manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 15 March 2011 Accepted: 24 May 2011
Published: 24 May 2011
References
1. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical
application. Nat Rev Cancer 2002, 2:342-350.
2. Korzeniewski N, Spardy N, Duensing A, Duensing S: Genomic instability
and cancer: Lessons learned from human papillomaviruses. Cancer Lett
2011, 305:113-122.
3. McLaughlin-Drubin ME, Munger K: The human papillomavirus E7
oncoprotein. Virology 2009, 384:335-344.
4. Longworth MS, Laimins LA: The binding of histone deacetylases and the
integrity of zinc finger-like motifs of the E7 protein are essential for the
life cycle of human papillomavirus type 31. J Virol 2004, 78:3533-3541.
5. Brehm A, Nielsen SJ, Miska EA, McCance DJ, Reid JL, Bannister AJ,
Kouzarides T: The E7 oncoprotein associates with Mi2 and histone
deacetylase activity to promote cell growth. EMBO J 1999, 18:2449-2458.
6. Hwang SG, Lee D, Kim J, Seo T, Choe J: Human papillomavirus type 16 E7
binds to E2F1 and activates E2F1-driven transcription in a
retinoblastoma protein-independent manner. J Biol Chem 2002,
277:2923-2930.
7. McLaughlin-Drubin ME, Huh KW, Munger K: Human papillomavirus type
16 E7 oncoprotein associates with E2F6. J Virol 2008, 82:8695-8705.
8. Nguyen CL, Munger K: Direct association of the HPV16 E7 oncoprotein
with cyclin A/CDK2 and cyclin E/CDK2 complexes. Virology 2008,
380:21-25.
9. He W, Staples D, Smith C, Fisher C: Direct activation of cyclin-dependent
kinase 2 by human papillomavirus E7. J Virol 2003, 77:10566-10574.
10. Duensing S, Munger K: Mechanisms of genomic instability in human
cancer: insights from studies with human papillomavirus oncoproteins.
Int J Cancer 2004, 109:157-162.
11. Nigg EA: Centrosome duplication: of rules and licenses. Trends Cell Biol
2007, 17:215-221.
12. Azimzadeh J, Bornens M: Structure and duplication of the centrosome.
J Cell Sci 2007, 120:2139-2142.
13. Ganem NJ, Godinho SA, Pellman D: A mechanism linking extra
centrosomes to chromosomal instability. Nature 2009, 460:278-282.
14. Duensing A, Spardy N, Chatterjee P, Zheng L, Parry J, Cuevas R,
Korzeniewski N, Duensing S: Centrosome overduplication, chromosomal
instability, and human papillomavirus oncoproteins. Environ Mol Mutagen
2009, 50:741-747.
15. Tsou MF, Wang WJ, George KA, Uryu K, Stearns T, Jallepalli PV: Polo kinase
and separase regulate the mitotic licensing of centriole duplication in
human cells. Dev Cell 2009, 17:344-354.
16. Kleylein-Sohn J, Westendorf J, Le Clech M, Habedanck R, Stierhof YD,
Nigg EA: Plk4-induced centriole biogenesis in human cells. Dev Cell 2007,
13:190-202.
17. Duensing S, Duensing A, Crum CP, Munger K: Human papillomavirus type
16 E7 oncoprotein-induced abnormal centrosome synthesis is an early
event in the evolving malignant phenotype. Cancer Res 2001,
61:2356-2360.
18. Duensing A, Liu Y, Perdreau SA, Kleylein-Sohn J, Nigg EA, Duensing S:
Centriole overduplication through the concurrent formation of multiple
daughter centrioles at single maternal templates. Oncogene 2007,
26:6280-6288.
19. Duensing A, Chin A, Wang L, Kuan SF, Duensing S: Analysis of centrosome
overduplication in correlation to cell division errors in high-risk human
papillomavirus (HPV)-associated anal neoplasms. Virology 2008,
372:157-164.
20. Korzeniewski N, Zheng L, Cuevas R, Parry J, Chatterjee P, Anderton B,
Duensing A, Munger K, Duensing S: Cullin 1 functions as a centrosomal
suppressor of centriole multiplication by regulating polo-like kinase 4
protein levels. Cancer Res 2009, 69:6668-6675.
21. Piel M, Meyer P, Khodjakov A, Rieder CL, Bornens M: The respective
contributions of the mother and daughter centrioles to centrosome
activity and behavior in vertebrate cells. J Cell Biol 2000, 149:317-330.
22. Habedanck R, Stierhof YD, Wilkinson CJ, Nigg EA: The Polo kinase Plk4
functions in centriole duplication. Nat Cell Biol 2005, 7:1140-1146.
23. Cunha-Ferreira I, Rodrigues-Martins A, Bento I, Riparbelli M, Zhang W,
Laue E, Callaini G, Glover DM, Bettencourt-Dias M: The SCF/Slimb ubiquitin
ligase limits centrosome amplification through degradation of SAK/PLK4.
Curr Biol 2009, 19:43-49.
24. Fode C, Binkert C, Dennis JW: Constitutive expression of murine Sak-a
suppresses cell growth and induces multinucleation. Mol Cell Biol 1996,
16:4665-4672.
25. Rogers GC, Rusan NM, Roberts DM, Peifer M, Rogers SL: The SCF Slimb
ubiquitin ligase regulates Plk4/Sak levels to block centriole
reduplication. J Cell Biol 2009, 184:225-239.
26. Karlseder J, Rotheneder H, Wintersberger E: Interaction of Sp1 with the
growth- and cell cycle-regulated transcription factor E2F. Mol Cell Biol
1996, 16:1659-1667.
27. Li J, Tan M, Li L, Pamarthy D, Lawrence TS, Sun Y: SAK, a new polo-like
kinase, is transcriptionally repressed by p53 and induces apoptosis upon
RNAi silencing. Neoplasia 2005, 7:312-323.
28. Duensing S, Munger K: Human papillomavirus type 16 E7 oncoprotein
can induce abnormal centrosome duplication through a mechanism
independent of inactivation of retinoblastoma protein family members.
J Virol 2003, 77:12331-12335.
29. Duensing A, Liu Y, Spardy N, Bartoli K, Tseng M, Kwon JA, Teng X,
Duensing S: RNA polymerase II transcription is required for human
papillomavirus type 16 E7- and hydroxyurea-induced centriole
overduplication. Oncogene 2007, 26:215-223.
doi:10.1186/1476-4598-10-61
Cite this article as: Korzeniewski et al.: The HPV-16 E7 oncoprotein
induces centriole multiplication through deregulation of Polo-like
kinase 4 expression. Molecular Cancer 2011 10:61.
Korzeniewski et al. Molecular Cancer 2011, 10:61
http://www.molecular-cancer.com/content/10/1/61
Page 5 of 5
